What does Rick Pazdur's new role mean for the FDA? And how much credit can the president take for lowering GLP-1 drug prices?
Shares rise 8.5% on enlicitide decanoate Phase 3 data showing LDL reduction. Q3 earnings beat at $2.58/share with $17.3B ...
Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in ...
The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.
Merck's enlicitide pill lowered LDL cholesterol by up to 60%, matching injectables like Repatha and offering an easier option ...
Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback